Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label long-term safety and tolerability study of SHR6508 injection in maintenance hemodialysis patients with secondary hyperparathyroidism
CTR20240033Phase 2Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of SHR6508 in secondary hyperparathyroidism (SHPT), chronic kidney disease (CKD), sponsored by Hengrui Therapeutics. Started Feb 2024; status: completed.
02
Drugs
SHR6508
03
Conditions
secondary hyperparathyroidism (SHPT)chronic kidney disease (CKD)
Beyond the preview
Go deeper on CTR20240033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240033.